News

Novo Nordisk Has Bought Three Early-Stage Obesity Drug Programmes From Kallyope — A First-in-Class Peptide Plus Two Small Molecules That Go Beyond GLP-1

By Mustafa Shariff, Editor in Chief · September 24,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Novo Nordisk Has Bought Three Early-Stage Obesity Drug Programmes From Kallyope — A First-in-Class Peptide Plus Two Small Molecules That Go Beyond GLP-1

Summary

  • Novo Nordisk Acquires Three Early-Stage Obesity Programmes From Kallyope — K-554 First-in-Class Peptide Heads a Beyond-GLP-1 Pipeline Push
  • Novo Nordisk acquired three early-stage obesity drug programmes from Kallyope (September 18, 2026) — K-554 IND-ready first-in-class peptide plus two small molecules targeting biology distinct from GLP-1/amylin, as Novo rebuilds its pipeline under investor pressure.

"Kallyope has built something genuinely novel — a neural-circuits discovery platform that targets biology that is distinct from, and likely complementary to, therapies targeting GLP-1 and amylin receptors. K-554 is a potentially first-in-class weekly peptide that is ready for an IND application. That is exactly the kind of asset Novo needs to build a pipeline that extends beyond semaglutide and into the next decade of obesity pharmacotherapy. This partnership deepens a relationship that has been productive for both companies since 2018."

Novo Nordisk's head of global research Jacob Petersen disclosed on September 18, 2026 via LinkedIn that the Danish pharmaceutical giant has acquired three early-stage obesity drug programmes from Kallyope Inc., a New York-based biotech backed by more than $400 million from Lux Capital, Polaris Partners, The Column Group, and Mubadala. Financial terms were not disclosed.
What Novo Is Buying
The lead asset is K-554 — a therapeutic peptide that Kallyope has described as a potentially first-in-class weekly treatment that targets biology that is 'distinct from, and likely complementary to, therapies targeting GLP-1 and amylin receptors.' K-554 is already at the investigational new drug application stage, meaning clinical trial entry could happen in the near term. Two additional small-molecule obesity candidates are also included in the transaction.
The 'distinct from GLP-1' characterisation is commercially significant. The current generation of obesity drugs — semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), and the next wave — all work primarily through GLP-1 and other incretin receptor mechanisms. A weekly therapeutic peptide that achieves meaningful weight reduction through a different biological pathway could be used as a monotherapy for patients who do not respond adequately to GLP-1 agonists, or combined with semaglutide for enhanced efficacy — a combination therapy approach that has produced dramatic weight loss results in early clinical studies.
The Investor Pressure Context
Novo Nordisk has faced an extraordinary reversal in the obesity market over the past 12 months. Having pioneered the modern GLP-1 obesity market with Wegovy, Novo has seen Eli Lilly's tirzepatide (Zepbound) overtake it in both clinical efficacy and US prescription volume — making Eli Lilly the new market leader in obesity pharmacotherapy that Novo had dominated since Wegovy's launch. Novo CEO Maziar Mike Doustdar, who also announced the departure of a further 4,000 staff this week, held a Capital Markets Day in London on September 21 to outline a turnaround strategy targeting $23 billion in annual pipeline revenue by 2035 and the launch of more than five multi-blockbuster drugs by 2030.
India's GLP-1 Connection
For BHC Media's India audience: Novo Nordisk's obesity pipeline strategy has direct India implications. The semaglutide API patent expired in India on March 20, 2026, triggering a wave of Indian generic launches (10+ brands, India GLP-1 market now Rs 2,055 crore). The next generation of obesity therapies — including beyond-GLP-1 mechanisms like Kallyope's K-554 — will eventually be commercialised in India, either as innovative products or as the basis for India's next generation of generic obesity medicines.
BHC Perspective
At Bengaluru Health Community, Novo's Kallyope acquisition is the global obesity pharmacotherapy story that best defines where the category is heading beyond GLP-1. For BHC founders building in metabolic health, diabetes management, or obesity technology — the 'beyond GLP-1' pipeline Novo is building through Kallyope and Orbis Medicines defines the next 5-10 year competitive landscape for the world's most commercially significant pharmaceutical category.
FAQs
Q: What did Novo Nordisk acquire from Kallyope?
A: Three early-stage obesity drug programmes — K-554 (IND-ready, potentially first-in-class weekly therapeutic peptide targeting biology distinct from GLP-1 and amylin receptors) plus two small-molecule obesity candidates. Announced September 18, 2026 by Novo's Head of Global Research. Financial terms not disclosed.
Q: Why is K-554 significant?
A: It targets obesity biology distinct from and complementary to GLP-1/amylin mechanisms — potentially effective for patients who don't respond to semaglutide/tirzepatide, and potentially combinable with existing GLP-1 agonists for enhanced weight loss. Weekly dosing, already at IND-ready stage.
Q: What is Novo Nordisk's broader strategic situation?
A: Lost obesity market leadership to Eli Lilly (Zepbound overtaking Wegovy in US prescriptions). September 21 Capital Markets Day: plans to reach $23B in revenue from current pipeline by 2035, launch 5+ multi-blockbusters by 2030. Also cut 4,000 more jobs and struck a $1.4B deal with Orbis Medicines for oral cardiometabolic drugs.